mRNA

#Biotech #Financing #mRNA #Seed funding

Biotech raises a €31.5m seed round to develop mRNA therapeutics

SRTD Biotech has announced the successful completion of an oversubscribed €31.5 million seed financing round.   The financing was led by Mérieux Equity Partners, with NRW.BANK and Boehringer Ingelheim Venture Fund joining the syndicate as co-leads. Lilly Ventures, HTGF, and the Freiburg-based family Office Anobis Asset also participated… Read More

#Business & Investment #News #Start-up Zone

#Epitopea #Immunotherapy #mRNA #Oncology #Ovarian cancer #Phase I trial

First patient receives mRNA immunotherapy for ovarian cancer

The first patient has been successfully dosed in OVACT, Epitopea’s first-in-human Phase I/Ib clinical trial evaluating its lead programme, CryptiVax-1001, targeting advanced high-grade serous ovarian cancer (HGSOC).  OVACT is designed to evaluate the safety, tolerability, immunogenicity, and early clinical activity of CryptiVax-1001 in HRP+/BRCA-wildtype advanced HGSOC patients. … Read More

#Cancer Research #News #Trending News

University of Queensland
#Advanced Research Projects Agency for Health (ARPA-H) #mRNA #RNA #University of Queensland

UQ selected by US government to develop RNA medicines

A United States Government agency has selected University of Queensland researchers to develop technology for personalised RNA medicines to be produced in hospitals, allowing lifesaving treatments to reach patients within days. UQ’s BASE mRNA Facility is part of a consortium of companies, universities and research institutes with potential… Read More

#News

#mRNA #Oncology #Phase I trial #Strand Therapeutics

First patients receive mRNA therapy for tumour-selective activation

Strand Therapeutics has dosed the first patients in its ASCENT-1 Phase I clinical trial of STX-003, an intravenously delivered self-replicating mRNA therapy designed to selectively express IL-12 within tumours while restricting expression in healthy tissue.   This is the first clinical evaluation of Strand’s SignalLock genetic circuitry, designed… Read More

#Cancer Research #News

#AI models #mRNA #Sanofi #ScionxBio #xRNA

ScionxBio collaborates to develop long-acting xRNA therapeutics 

ScionxBio, a preclinical-stage biotechnology company developing next-generation mRNA therapeutics, has entered into a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialise extended exposure versions of certain Sanofi mRNA candidates by leveraging ScionxBio’s platform.  The agreement brings together the global expertise of Sanofi’s mRNA… Read More

#News

mRNA
#In vitro #mRNA #Whitepaper

Whitepaper: Explore a new approach to IVT capping

Download this new Whitepaper from Aldevron to learn about a novel RNA polymerase designed to support high-quality mRNA production. Supports co-transcriptional capping during in vitro transcription (IVT) Designed to work efficiently with commercially available cap analogs Helps researchers generate high-quality mRNA transcripts Access the full Whitepaper to explore IVT capping… Read More

#News

#BioNTech #Head and neck cancer #Immunotherapy #mRNA #Phase III trial

BioNTech’s mRNA immunotherapy fails to meet primary endpoint

BioNTech has announced the first topline results from the AHEAD-MERIT Phase II/III clinical trial for its investigational mRNA cancer immunotherapy BNT113 (tenumomeran/raplemomeran or tenu-ra).  The clinical trial is evaluating BNT113 in combination with pembrolizumab compared to pembrolizumab monotherapy as a first-line treatment for patients with unresectable recurrent… Read More

#Cancer Research #News

mRNA
#Drug discovery #eBook #Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines

Discover mRNA: Beyond vaccines to personalised medicine

Despite a challenging funding landscape, 2026 has seen two groundbreaking advances in mRNA vaccine discovery; the first-ever mRNA seasonal influenza vaccine for adults and the first positive Phase III readout for an mRNA-based cancer therapy. This eBook explores how the mRNA platform has evolved since its use in Covid-19 vaccines,… Read More

#News

RNA vaccine
#Immunology / Virology & Vaccines #Influenza #mRNA #mRNA-based vaccines

mRNA vaccine produces more diversified antibody response

A new study has revealed how an mRNA-based influenza vaccine reshapes immune responses at the cellular and molecular levels.   By tracking germinal-centre (GC) activity and individual secreted antibody clonotypes for up to six months, researchers uncovered how vaccination drives the evolution and diversification of immune responses.  … Read More

#News

Flu vaccine
#GSK #Immunology / Virology & Vaccines #Influenza #mRNA #mRNA-based vaccines

GSK reveals plans to advance mRNA flu vaccine to Phase III

GSK has revealed that its mRNA seasonal influenza (flu) vaccine candidate has shown higher immune responses against all influenza strains tested compared to licensed standard dose and high dose inactivated flu vaccines.  The Phase II data were presented at the OPTIONS XIII Conference for the Control of… Read More

#News

#Autoimmune disease #etherna #mRNA #Multiple sclerosis #Type 1 diabetes

mRNA technology could treat autoimmune diseases, study shows

mRNA technology could help treat autoimmune diseases such as multiple sclerosis and type 1 diabetes, researchers say.  Scientists at the Biomedical Research Institute (BIOMED) at Hasselt University and the Belgian biotech company etherna have demonstrated that mRNA technology, which gained recognition for its use in Covid-19 vaccines, also holds promise for the targeted… Read More

#Editor's Choice #News

Bacteria in Petri dishes
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Covid-19 #mRNA #mRNA-based vaccines #Oncology #RNA

How drug discovery is tackling global health challenges

This is the latest episode of the free DDW Narrated Podcast. The episode covers two articles written for DDW Volume 25, Issue 2, Spring 2024. The first article is called ‘Why more work is needed to fight antimicrobial resistance’. In the article, DDW Editor Reece Armstrong speaks to Professor… Read More

#Featured Podcasts

BioNTech HQ
#BioNTech #Drug discovery #mRNA

BioNTech co-founders launch new mRNA company

An independent company is to be established and led by BioNTech co-founders Professor Ugur Sahin and Professor Özlem Türeci to “advance next-generation mRNA innovations”.   BioNTech has announced plans to contribute related rights and mRNA technologies to the new company to support the prioritised development of mRNA innovations… Read More

#Business & Investment #News

mRNA
#CEPI #Immunology / Virology & Vaccines #Influenza #Moderna #mRNA #Pandemic prevention #Pandemic response

$54.3m CEPI investment boosts Moderna’s H5 influenza vaccine

The Coalition for Epidemic Preparedness Innovations (CEPI) is to invest up to $54.3 million to support a pivotal Phase III clinical trial that aims to help advance Moderna’s investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, to licensure.   The organisation says the funding marks a significant step… Read More

#Business & Investment #News

Business financing
#Financing #mRNA #Oncology #Strand Therapeutics

Strand Therapeutics raises $153 million for mRNA therapies

Strand Therapeutics has announced a $153 million Series B funding led by Kinnevik, with new investors including Regeneron Ventures, ICONIQ, and Amgen Ventures.  The funding will advance Strand’s pipeline, led by STX-001, a programmable mRNA therapy that expresses the cytokine interleukin-12 (IL-12) directly from the tumour microenvironment. … Read More

#Business & Investment #News